Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

被引:117
|
作者
Higashihara, Eiji [2 ]
Torres, Vicente E. [1 ]
Chapman, Arlene B. [3 ]
Grantham, Jared J. [4 ]
Bae, Kyongtae [5 ]
Watnick, Terry J. [6 ]
Horie, Shigeo [7 ]
Nutahara, Kikuo [2 ]
Ouyang, John [8 ]
Krasa, Holly B. [8 ]
Czerwiec, Frank S. [8 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Coll Med, Rochester, MN 55905 USA
[2] Kyorin Univ, Sch Med, Tokyo, Japan
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Teikyo Univ, Sch Med, Tokyo 173, Japan
[8] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA
基金
美国国家卫生研究院;
关键词
DIETARY-PROTEIN RESTRICTION; BLOOD-PRESSURE CONTROL; VOLUME PROGRESSION;
D O I
10.2215/CJN.03530411
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses of primary and secondary end points included LMM using all subject data and mixed model repeated measures (MMRM) of change from baseline at each year. Pearson correlation tested the association between log-TKV and eGFR changes. Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls 1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m(2)) were similar. Control TKV increased 5.8% versus 1.7%/yr for tolvaptan (P < 0.001, estimated ratio of geometric mean 0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined: -2.1 versus -0.71 ml/min per 1.73 m(2)/yr (P = 0.01, LMM group difference 1.1 ml/min per 1.73 m(2)/yr [95% confidence interval 0.24 to 1.9]). Sensitivity analyses including withdrawn subjects were similar, whereas MMRM analyses were significant at each year for TKV and nonsignificant for eGFR. Increasing TKV correlated with decreasing eGFR (r = -0.21, P < 0.01). Conclusion ADPKD cyst growth progresses more slowly with tolvaptan than in historical controls, but AEs are common. Clin J Am Soc Nephrol 6: 2499-2507, 2011. doi: 10.2215/CJN.03530411
引用
收藏
页码:2499 / 2507
页数:9
相关论文
共 50 条
  • [21] Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Erickson, Kevin F.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (06) : 382 - +
  • [22] Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease
    Betts, Keith A.
    Nunna, Sasikiran
    Kumar, Retesh
    Nie, Xiaoyu
    Fernandes, Ancilla W.
    KIDNEY MEDICINE, 2024, 6 (04)
  • [23] Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Koch, Gary
    Ouyang, John
    McQuade, Robert D.
    Blais, Jaime D.
    Czerwiec, Frank S.
    Sergeyeva, Olga
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1930 - 1942
  • [24] Lithiasic complication in autosomal dominant polycystic kidney disease: An experience of 15 years
    Strakosha, Ariana
    Idrizi, Alma
    Barbullushi, Myftar
    Bakallbashi, Katjusha
    Dedej, Teuta
    Thereska, Nestor
    Kodra, Sulejman
    Koroshi, Alketa
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 355 - 355
  • [25] In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”
    Shigeo Horie
    Satoru Muto
    Clinical and Experimental Nephrology, 2016, 20 : 149 - 150
  • [26] In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease"
    Horie, Shigeo
    Muto, Satoru
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 149 - 150
  • [27] Multicenter Real-Life Experience With Tolvaptan Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease
    Duriseti, Parikshit
    Wigerinck, Stijn
    Chedid, Maroun
    Radhakrishnan, Yeshwanter
    Mao, Michael A.
    Hommos, Musab S.
    Garg, Arvind K.
    Zoghby, Ziad
    Keddis, Mira T.
    Trautman, Christopher L.
    Dahlen, Erin
    Gay, Melissa K.
    Mcfadden, Jennifer E.
    Bhat, Samrat V.
    Harris, Peter C.
    Erickson, Stephen B.
    Hogan, Marie C.
    Torres, Vicente E.
    Chebib, Fouad T.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 161 - 161
  • [28] Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
    Horie, Shigeo
    KIDNEY INTERNATIONAL, 2015, 88 (01) : 14 - 16
  • [29] Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
    Rodney D. Gilbert
    Hazel Evans
    Kazeem Olalekan
    Arvind Nagra
    Mushfequr R. Haq
    Mark Griffiths
    Pediatric Nephrology, 2017, 32 : 893 - 896
  • [30] Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?
    Hartung, Erum A. A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (01): : 11 - 13